AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. PDSB
  4. [8-K] PDS Biotechnology Corporation Reports Material Event

[8-K] PDS Biotechnology Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

PDS Biotechnology Corporation (NASDAQ: PDSB) filed a Form 8-K on June 25, 2025 under Item 8.01 to announce that it has updated its corporate presentation deck. The new June 2025 slide deck is furnished as Exhibit 99.1 and incorporated by reference into the filing. No financial statements, earnings figures, strategic transactions, or other material events were disclosed. Investors should review the furnished deck for any updated development timelines or clinical program highlights; however, the 8-K itself contains no additional quantitative or qualitative information.

PDS Biotechnology Corporation (NASDAQ: PDSB) ha presentato un modulo 8-K il 25 giugno 2025 ai sensi della voce 8.01 per annunciare l'aggiornamento della sua presentazione aziendale. Il nuovo set di slide di giugno 2025 猫 fornito come Allegato 99.1 e incorporato per riferimento nella documentazione. Non sono stati divulgati bilanci, dati sugli utili, transazioni strategiche o altri eventi rilevanti. Gli investitori sono invitati a consultare il materiale fornito per eventuali aggiornamenti sui tempi di sviluppo o sui punti salienti dei programmi clinici; tuttavia, il modulo 8-K non contiene ulteriori informazioni quantitative o qualitative.

PDS Biotechnology Corporation (NASDAQ: PDSB) present贸 un Formulario 8-K el 25 de junio de 2025 bajo el punto 8.01 para anunciar que ha actualizado su presentaci贸n corporativa. La nueva presentaci贸n de diapositivas de junio de 2025 se adjunta como Anexo 99.1 y se incorpora por referencia en el documento. No se divulgaron estados financieros, cifras de ganancias, transacciones estrat茅gicas ni otros eventos materiales. Se recomienda a los inversores revisar la presentaci贸n proporcionada para conocer cualquier actualizaci贸n en los cronogramas de desarrollo o aspectos destacados de los programas cl铆nicos; sin embargo, el 8-K en s铆 no contiene informaci贸n cuantitativa o cualitativa adicional.

PDS Biotechnology Corporation (NASDAQ: PDSB)電� 2025雲� 6鞗� 25鞚� 頃 8.01鞐� 霐半澕 Form 8-K毳� 鞝滌稖頃橃棳 須岇偓 頂勲爤鞝犿厡鞚挫厴 鞛愲毳� 鞐呺嵃鞚错姼頄堨潓鞚� 氚滍憸頄堨姷雼堧嫟. 2025雲� 6鞗� 斓滌嫚 鞀澕鞚措摐 鞛愲電� 鞝勳嫓氍� 99.1搿� 鞝滉车霅橂┌ 鞝滌稖 靹滊鞐� 彀戈碃搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞛鞝滍憸, 靾橃澋 靾橃箻, 鞝勲灥鞝� 瓯半灅 霕愲姅 旮绊儉 欷戩殧頃� 靷贝鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 韴瀽鞛愲摛鞚� 鞐呺嵃鞚错姼霅� 臧滊皽 鞚检爼鞚措倶 鞛勳儊 頂勲攴鸽灗 欤检殧 雮挫毄鞚� 頇曥澑頃橁赴 鞙勴暣 鞝滉车霅� 鞛愲毳� 瓴�韱犿暣鞎� 頃橃毵�, 8-K 氤鸽鞐愲姅 於旉皜鞝侅澑 鞝曤焿鞝� 霕愲姅 鞝曥劚鞝� 鞝曤炒臧� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

PDS Biotechnology Corporation (NASDAQ : PDSB) a d茅pos茅 un formulaire 8-K le 25 juin 2025 en vertu de l'article 8.01 pour annoncer la mise 脿 jour de sa pr茅sentation d'entreprise. Le nouveau diaporama de juin 2025 est fourni en tant que Pi猫ce 99.1 et incorpor茅 par r茅f茅rence dans le dossier. Aucun 茅tat financier, chiffre de b茅n茅fices, transaction strat茅gique ou autre 茅v茅nement important n'a 茅t茅 divulgu茅. Les investisseurs sont invit茅s 脿 consulter le diaporama fourni pour tout calendrier de d茅veloppement mis 脿 jour ou point fort des programmes cliniques ; toutefois, le 8-K lui-m锚me ne contient aucune information quantitative ou qualitative suppl茅mentaire.

PDS Biotechnology Corporation (NASDAQ: PDSB) reichte am 25. Juni 2025 ein Formular 8-K unter Punkt 8.01 ein, um die Aktualisierung seiner Unternehmenspr盲sentation bekannt zu geben. Das neue Folienpaket von Juni 2025 ist als Anlage 99.1 beigef眉gt und wird durch Verweis in die Einreichung aufgenommen. Es wurden keine Finanzberichte, Gewinnzahlen, strategische Transaktionen oder sonstige wesentliche Ereignisse offengelegt. Investoren sollten die bereitgestellten Folien auf aktualisierte Entwicklungszeitpl盲ne oder klinische Programm-Highlights 眉berpr眉fen; das 8-K selbst enth盲lt jedoch keine weiteren quantitativen oder qualitativen Informationen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Administrative 8-K; only furnishes updated investor deck, no new financial or strategic data鈥攏eutral market impact.

The filing is limited to Item 8.01, indicating no binding commitments or financial disclosures. While a refreshed presentation can refine messaging and reveal incremental clinical details, those specifics are not included in the 8-K text. Until investors review Exhibit 99.1, the market impact remains neutral. Overall, this is routine investor-relations housekeeping.

TL;DR: Routine corporate communication; satisfies disclosure obligations by publicly posting the latest slide deck.

The company fulfills Regulation FD by furnishing the presentation via EDGAR, ensuring equal information access. No board actions, officer changes, or governance shifts are reported. Compliance appears intact, and the event is non-material from a governance-risk perspective.

PDS Biotechnology Corporation (NASDAQ: PDSB) ha presentato un modulo 8-K il 25 giugno 2025 ai sensi della voce 8.01 per annunciare l'aggiornamento della sua presentazione aziendale. Il nuovo set di slide di giugno 2025 猫 fornito come Allegato 99.1 e incorporato per riferimento nella documentazione. Non sono stati divulgati bilanci, dati sugli utili, transazioni strategiche o altri eventi rilevanti. Gli investitori sono invitati a consultare il materiale fornito per eventuali aggiornamenti sui tempi di sviluppo o sui punti salienti dei programmi clinici; tuttavia, il modulo 8-K non contiene ulteriori informazioni quantitative o qualitative.

PDS Biotechnology Corporation (NASDAQ: PDSB) present贸 un Formulario 8-K el 25 de junio de 2025 bajo el punto 8.01 para anunciar que ha actualizado su presentaci贸n corporativa. La nueva presentaci贸n de diapositivas de junio de 2025 se adjunta como Anexo 99.1 y se incorpora por referencia en el documento. No se divulgaron estados financieros, cifras de ganancias, transacciones estrat茅gicas ni otros eventos materiales. Se recomienda a los inversores revisar la presentaci贸n proporcionada para conocer cualquier actualizaci贸n en los cronogramas de desarrollo o aspectos destacados de los programas cl铆nicos; sin embargo, el 8-K en s铆 no contiene informaci贸n cuantitativa o cualitativa adicional.

PDS Biotechnology Corporation (NASDAQ: PDSB)電� 2025雲� 6鞗� 25鞚� 頃 8.01鞐� 霐半澕 Form 8-K毳� 鞝滌稖頃橃棳 須岇偓 頂勲爤鞝犿厡鞚挫厴 鞛愲毳� 鞐呺嵃鞚错姼頄堨潓鞚� 氚滍憸頄堨姷雼堧嫟. 2025雲� 6鞗� 斓滌嫚 鞀澕鞚措摐 鞛愲電� 鞝勳嫓氍� 99.1搿� 鞝滉车霅橂┌ 鞝滌稖 靹滊鞐� 彀戈碃搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞛鞝滍憸, 靾橃澋 靾橃箻, 鞝勲灥鞝� 瓯半灅 霕愲姅 旮绊儉 欷戩殧頃� 靷贝鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�. 韴瀽鞛愲摛鞚� 鞐呺嵃鞚错姼霅� 臧滊皽 鞚检爼鞚措倶 鞛勳儊 頂勲攴鸽灗 欤检殧 雮挫毄鞚� 頇曥澑頃橁赴 鞙勴暣 鞝滉车霅� 鞛愲毳� 瓴�韱犿暣鞎� 頃橃毵�, 8-K 氤鸽鞐愲姅 於旉皜鞝侅澑 鞝曤焿鞝� 霕愲姅 鞝曥劚鞝� 鞝曤炒臧� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

PDS Biotechnology Corporation (NASDAQ : PDSB) a d茅pos茅 un formulaire 8-K le 25 juin 2025 en vertu de l'article 8.01 pour annoncer la mise 脿 jour de sa pr茅sentation d'entreprise. Le nouveau diaporama de juin 2025 est fourni en tant que Pi猫ce 99.1 et incorpor茅 par r茅f茅rence dans le dossier. Aucun 茅tat financier, chiffre de b茅n茅fices, transaction strat茅gique ou autre 茅v茅nement important n'a 茅t茅 divulgu茅. Les investisseurs sont invit茅s 脿 consulter le diaporama fourni pour tout calendrier de d茅veloppement mis 脿 jour ou point fort des programmes cliniques ; toutefois, le 8-K lui-m锚me ne contient aucune information quantitative ou qualitative suppl茅mentaire.

PDS Biotechnology Corporation (NASDAQ: PDSB) reichte am 25. Juni 2025 ein Formular 8-K unter Punkt 8.01 ein, um die Aktualisierung seiner Unternehmenspr盲sentation bekannt zu geben. Das neue Folienpaket von Juni 2025 ist als Anlage 99.1 beigef眉gt und wird durch Verweis in die Einreichung aufgenommen. Es wurden keine Finanzberichte, Gewinnzahlen, strategische Transaktionen oder sonstige wesentliche Ereignisse offengelegt. Investoren sollten die bereitgestellten Folien auf aktualisierte Entwicklungszeitpl盲ne oder klinische Programm-Highlights 眉berpr眉fen; das 8-K selbst enth盲lt jedoch keine weiteren quantitativen oder qualitativen Informationen.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 25, 2025


PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
 001-37568
26-4231384
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
303A College Road East, Princeton, NJ 08540
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.00033 per share
 PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01
Other Events.

On June 25, 2025, the Company updated its corporate presentation deck.

A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
  
Description
     
99.1
  
Corporate Presentation (June 2025).
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
   
Date:  June 25, 2025
By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name: Frank Bedu-Addo, Ph.D.
 
Title: President and Chief Executive Officer


Source:

FAQ

What did PDS Biotechnology (PDSB) file on June 25, 2025?

A Form 8-K announcing it has updated its corporate presentation, furnished as Exhibit 99.1.

Does the 8-K include any financial results or guidance?

No. The filing solely references the updated presentation and contains no financial statements or earnings data.

Where can investors access the new PDSB corporate presentation?

The slide deck is available on EDGAR as Exhibit 99.1 to the June 25, 2025 Form 8-K.

Are there any material transactions or management changes disclosed?

No. The 8-K lists no acquisitions, divestitures, executive departures, or board actions.

Why did PDS Biotechnology use Item 8.01 for this disclosure?

Item 8.01 allows companies to furnish information they deem of interest to security holders; here, the updated investor deck.
Stock PDSB logo
Pds Biotechnology Corporation

NASDAQ:PDSB

PDSB Rankings

#7399 Ranked by Market Cap
N/A Ranked by Dividends

PDSB Latest News

Jul 10, 2025
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
Jun 9, 2025
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune庐 HPV for the Treatment of HPV16+ HNSCC
Jun 2, 2025
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune庐 HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2025
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune庐 HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 20, 2025
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

PDSB Latest SEC Filings

Jul 10, 2025
[8-K] PDS Biotechnology Corporation Reports Material Event

PDSB Stock Data

58.05M
44.30M
3.11%
9.57%
10.48%
Biotechnology
Pharmaceutical Preparations
United States
PRINCETON